Mounjaro in Australia

For weight management, the Australian Product Information (PI) revised 2 October 2026 covers "adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes mellitus)", as "an adjunct to a reduced-calorie diet and increased physical activity".

Weight management and sleep apnoea are adult uses only. Children and adolescents aged 10 and over weighing 50 kg or more can use it for type 2 diabetes, at 5 mg or 10 mg; the PI advises caution stepping up to 10 mg at 60 kg or less, because safety data are limited and exposure may exceed that of an adult on 15 mg.

It is not for type 1 diabetes or diabetic ketoacidosis. The only contraindication is hypersensitivity to tirzepatide or an ingredient.

Each KwikPen holds four fixed weekly doses of one strength. The dose knob must be turned until it stops at the "1" icon; the PI warns the pen can underdose if used incorrectly. Liquid left after the fourth dose is normal and should not be injected, and the pen will not dial a fifth full dose.

It is injected under the skin of the abdomen or thigh, at any time of day, with or without food, on the same day each week, rotating the site. The Australian PI and CMI do not list the upper arm.

Unlike the US label for Zepbound, the Australian PI has no boxed thyroid warning and does not rule out people with a personal or family history of medullary thyroid carcinoma or MEN 2; thyroid tumours in rats are described in the non-clinical section. Mounjaro carries the black triangle (▼) for additional monitoring because its indications were extended.

The PI's main warnings and interactions:

The journal papers lead with the treatment-regimen estimand, which counts results regardless of whether people stopped treatment. The Australian PI reports the efficacy estimand, which gives higher figures for the same trial. The table says which is quoted.

In SURMOUNT-4, 670 adults who had reached 10 or 15 mg in a 36-week open-label lead-in, losing an average 20.9%, were randomised to continue tirzepatide or switch to placebo for 52 weeks. The placebo group regained 14.0% of body weight; the tirzepatide group lost a further 5.5%. At the end, 16.6% of the placebo group and 89.5% of the tirzepatide group had kept at least 80% of the weight lost (JAMA 2024, treatment-regimen). The PI reports +14.8% against -6.7%, and notes the placebo group's average weight at week 88 was still below its weight before the lead-in.

In the three-year SURMOUNT-1 group with prediabetes, 2.4% of the tirzepatide group and 13.7% of the placebo group had type 2 diabetes seventeen weeks after treatment stopped.

The PI has no stopping rule based on weight response, unlike the liraglutide and naltrexone-bupropion PIs. It says to stop for suspected pancreatitis and before a planned pregnancy, to consider a dose change or stopping for severe gut symptoms, and to consider stopping for severe or persistent malnutrition. The CMI says not to stop suddenly without talking to the prescriber.

Neither document gives a tapering schedule, and no Australian guidance on tapering was found. Australian Prescriber (December 2025) says "when treatment is stopped, regaining weight is the norm", and that a dose reduction can be considered instead of stopping when side effects are mild and gut-related.

Mounjaro is a Schedule 4 (prescription only) medicine. With no PBS listing there is no authority step: a doctor writes a private script for a registered use and any pharmacy can fill it at its own price.

The Medical Board of Australia's telehealth guidelines say prescribing without a real-time consultation is not good practice, including requests "based on the patient completing a health questionnaire" when the practitioner has never spoken with the patient. On 16 September 2026 AHPRA said it was investigating high-volume and single-treatment business models, including those for GLP-1 weight-loss medicines. A separate page compares telehealth services that prescribe Mounjaro.

LillyDirect, launched by Lilly with Evermed on 22 September 2026, takes an e-script from the patient's prescriber, sends it to a third-party pharmacist and delivers to the home. The Pharmacy Guild and the Pharmaceutical Society of Australia called the model "clinically inferior".

Pharmacy compounding of GLP-1 receptor agonists, including tirzepatide, has been prohibited since 1 October 2024. In October 2026 the TGA announced that two Victorian individuals had paid infringement notices of $7,920 (two notices) and $3,960 (one) for allegedly importing Mounjaro pens not entered on the ARTG. In March 2026 TGA testing found imported products labelled as GLP-1 medicines that contained none.